Knight Therapeutics Announces Launch of Minjuvi® in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi ® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. Minjuvi ® is indicated in combination with lenalidomide, followed by Minjuvi ® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

DLBCL, the most common subtype of non-Hodgkin lymphoma, presents an aggressive clinical profile. Although a significant number of patients can be cured with standard front-line therapy, many will exhibit refractory disease or relapse following an initial response and are ineligible to transplant. These patients face a very poor prognosis and need novel treatment option to improve their outcomes ¹ .

According to NCCN Guidelines, Minjuvi ^® is listed as one of the preferred 2 ^nd line treatments for DLBCL patients who are ineligible for transplantation ² . The marketing authorization was based on the data from L-MIND study, an open label, multicenter, single arm Phase 2 trial. The primary endpoint results showed an objective response rate (ORR) of 60%, which includes a complete response rate (CR) of 43% and a disease control rate (DCR) of 75% ³ .

"The launch of Minjuvi ^® brings a new treatment option to relapsed or refractory non-transplant eligible DLBCL adult patients due to its innovative characteristics and proven efficacy, with a reasonable safety profile," said Dr Guilherme Perini, hematologist specialized in Lymphomas at Hospital Israelita Albert Einstein. "Minjuvi ^® will improve patients' standard of care and it is a highly anticipated therapy for our patients," added Dr Perini.

In September 2021, Knight entered into a supply and distribution agreement with Incyte (NASDAQ: INCY), for the exclusive rights to distribute pemigatinib (Pemazyre ^® ) as well as tafasitamab (sold as Monjuvi ^® in the United States and Minjuvi ^® in Europe) in Latin America. In July 2023, ANVISA (Agência Nacional de Vigilância Sanitária) granted Market Authorization for Minjuvi ^® under the rare disease designation according to Resolution RDC 205/2017. Additionally, in October 2023, Knight received pricing approval for Minjuvi ^® from the Drugs Market Regulation Chamber ("CMED").

"In line with Knight's commitment to advancing healthcare in Latin America, we are excited to launch Minjuvi in Brazil, an innovative treatment option for addressing a current unmet medical need," said Samira Sakhia, Knight Therapeutics President and CEO.

"Knight's team in Brazil is thrilled to make Minjuvi ^® available to health care professionals and centers, improving DLBCL patient care in the country," said Cristiane Coelho, Knight Therapeutics Brazil General Manager.

About Tafasitamab (Minjuvi ^® )

Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. In 2024, Incyte was assigned such license and now exclusively holds such rights. Tafasitamab incorporates an XmAb ^® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).

In the United States, Monjuvi ^® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplantation (ASCT). This indication has received accelerated approval based on the overall response rate. Continued approval for this indication may be contingent upon verification and description of the clinical benefit in confirmatory trial(s). Please see the U.S. full Prescribing Information for Monjuvi for important safety information.

In Europe, Minjuvi ^® (tafasitamab) received conditional marketing authorization, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials. Its safety and efficacy for these investigational indications have not been established in pivotal trials.

Minjuvi ^® and Monjuvi ^® are registered trademarks of Incyte. Tafasitamab is marketed under the brand name Monjuvi ^® in the U.S. and under the brand name Minjuvi ^® in Europe, the United Kingdom and Canada.

XmAb ^® is a registered trademark of Xencor, Inc.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca .

Forward-Looking Statements for Knight Therapeutics Inc.

This document may contain forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2022 as filed on www.sedarplus.ca . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.

References:

Araújo, G et al. (2023). Landscape of Diffuse Large B-Cell Lymphoma (DLBCL) in Brazilian Public Healthcare System (SUS). 2023-11, ISPOR Europe 2023, Copenhagen, Denmark. Value in Health, Volume 26, Issue 11, S2 (December 2023). Available at https://www.ispor.org/docs/default-source/euro2023/postereph246131853-pdf.pdf?sfvrsn=17d37f1a_0
National Comprehensive Cancer Network (NCCN) Guidelines. B-Cell Lymphomas dated January 18, 2024. Accessible at: Treatment by Cancer Type (nccn.org)
Duell, J et al. (2021). Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958

CONTACT INFORMATION:

Knight Therapeutics Inc.

Samira Sakhia		Arvind Utchanah
President & Chief Executive Officer		Chief Financial Officer
T: 514.484.4483		T. +598.2626.2344
F: 514.481.4116
Email: IR@knighttx.com		Email: IR@knighttx.com
Website: www.knighttx.com		Website: www.knighttx.com

News Provided by GlobeNewswire via QuoteMedia

Knight Therapeutics GUD:CA Medical Device Investing

GUD:CA

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 24, 2024

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2024 before the market opens on Wednesday, July 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.

During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 023107. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com . The earnings press release and related information can also be found in that section of our website under the heading "Financials." A replay of the call will be available under "News, Events & Presentations" through Wednesday, August 7, 2024.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Medtronic announces departure of Karen Parkhill, Chief Financial Officer

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Karen Parkhill will resign as executive vice president and chief financial officer to accept the role of chief financial officer for HP Inc.

"On behalf of our employees, our executive committee and our board of directors, I want to thank Karen for her leadership over the last eight years. I am personally grateful to Karen for her support through my transition to CEO, navigating the pandemic and delivering a new operating model for the company. We wish her all the best as she takes on the next chapter of her career," said Geoff Martha , Medtronic chairman and chief executive officer. "Across the company, we're building momentum with our innovation-driven growth strategy, and we remain focused and committed to delivering on our short- and longer-term financial objectives."

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

New MiniMed 780G system data demonstrates ability to address persistent blood sugar challenges for people with type 1 diabetes

With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn phenomenon, and improved overnight sleep

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a comprehensive body of new data at the American Diabetes Association's (ADA) 84 th Scientific Sessions that showcases the benefits of the MiniMed™ 780G system. New data shows how the system addresses hyperglycemia and nighttime burden, adding to the established body of evidence that demonstrates the system's ability to tackle unique and burdensome challenges of diabetes, such as managing highs and meal-time management or carb counting, while also mirroring outcomes across a wide-ranging patient population.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Sempra Appoints Jennifer M. Kirk to Board of Directors

Sempra (NYSE: SRE) (BMV: SRE) today announced the appointment of Jennifer M. Kirk to the company's board of directors effective June 20 2024. Kirk is currently the global controller and chief accounting officer of Medtronic plc (NYSE: MDT) and has deep executive experience in finance, accounting and capital market activities, including more than 20 years in the energy industry.

"Bringing new perspectives into the boardroom is a critical component of our effort to support the company's mission to build North America's premier energy infrastructure company," said Jeffrey W. Martin , Sempra chairman and CEO. "Our board of directors embody a diverse set of skills, experiences and viewpoints that help guide Sempra's corporate strategy and overall business success. Jennifer's strong accounting and finance experience, coupled with her understanding of the energy business, will be a great complement to the board as we advance our corporate strategy and oversee financial discipline, risk management and ethical practices."

Before joining Medtronic, Kirk, 49, worked at Occidental Petroleum Corporation for more than two decades, serving in roles of increasing responsibility, including senior vice president of integration and value capture, and vice president, controller and principal accounting officer.

Kirk serves on the board of directors of Republic Services, where she is chair of the audit committee. She holds a bachelor's degree in economics from UC Santa Barbara and a master's degree in business administration from California State University, Bakersfield .

With the appointment of Kirk, Sempra will have 10 directors with three having been newly elected over the past five years, reflecting the company's commitment to periodic board refreshment to ensure fresh and diverse perspectives are present in the boardroom. Kirk will serve on the board's audit committee and the safety, sustainability and technology committee.

About Sempra
Sempra (NYSE: SRE) is a leading North American energy infrastructure company focused on delivering energy to nearly 40 million consumers. As owner of one of the largest energy networks on the continent, Sempra is electrifying and improving the energy resilience of some of the world's most significant economic markets, including California , Texas , Mexico and global energy markets. The company is recognized as a leader in sustainable business practices and for its high-performance culture focused on safety and operational excellence, as demonstrated by Sempra's inclusion in the Dow Jones Sustainability Index North America and in The Wall Street Journal's Best Managed Companies. More information about Sempra is available at sempra.com and on social media @Sempra .

View original content to download multimedia: https://www.prnewswire.com/news-releases/sempra-appoints-jennifer-m-kirk-to-board-of-directors-302177421.html

SOURCE Sempra

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Contacts:

Erika Winkels	Ryan Weispfenning
Public Relations	Investor Relations
+1 (763) 526-8478	+1 (763) 505-4626

Safety and Glycemic Outcomes Using the MiniMed™ 780G system with an All-in-One Disposable Sensor with Transmitter 3-month study period (n=109, ages 7-17; n=107, ages 18-80)
	Youths (ages 7-17)			Adults (ages 18-80)
	Run-in (N=112)	Study (N=109)	ROS (N=41)	Run-in (N=110)	Study (N=107)	ROS (N=44)
Time in Smart Guard, %	14.5 ± 31.3	93.5±11.3	96.9±3.1	33.2±40.3	96.6±6.6	97.5±3.7



Mean SG, mg/dL	180.4±27.1	154.4±17.6	149.0±15.3	161.0±18.7	142.2±12.8	136.5±12.0

Percentage of time spent at glucose ranges
(% TBR)	1.6±1.7	1.9±1.4	1.9±1.2	1.7±1.9	1.5±1.4	1.7±1.4

70-140 mg/dL (% TITR)	32.1±14.1	49.2±9.7	52.7±9.2	39.2±13.0	56.1±10.5	61.6±9.9

70-180 mg/dL (% TIR)	54.4±15.7	71.4±9.9	74.7±9.3	66.5±12.6	80.2±8.1	83.8±7.4

>180 mg/dL (% TAR)	44.0±16.1	26.7±10.1	23.3±9.4	31.8±13.1	18.2±8.4	14.5±7.7

Contacts:
Ashley Patterson	Ryan Weispfenning
Public Relations	Investor Relations
+1 (818) 576-3025	+1 (763) 505-4626

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

Latest News

Latest Press Releases

Related News

TOP STOCKS